Emmanuel J Favaloro/LinkedIn
Aug 21, 2025, 14:55
Emmanuel Favaloro on DOACs Versus Warfarin in the COVID19 Era
“Did the COVID19 pandemic push the use of DOACs to the lead in the ‘anticoagulant race’, and ahead of warfarin?
Well, yes and no.
Depends on where you live. Check out this Commentary in Seminars in Thrombosis and Hemostasis.
Just released online.
Enjoy!”
Stay informed with Hemostasis Today.
-
Jan 15, 2026, 15:09Louise St Germain Bannon: ISTH Education is Off to An Exciting Start in 2026
-
Jan 15, 2026, 13:12Michele Romoli: What is The Optimal Treatment Strategy After Stroke While on DOAC?
-
Jan 15, 2026, 12:18Isabelle Mahé on Reduced Dose Apixaban and Cancer-Associated VTE
-
Jan 15, 2026, 04:52Lucien Blondel on Resolve Stroke: To Be Used In the SCULPT Trial
-
Jan 15, 2026, 04:40Mitchell Elkind: Mental Disorders, Brain Health, and Acute Coronary Syndrome
-
Jan 15, 2026, 04:31Laura Dormer on Comparing Stroke Care in Medicare Advantage Versus Fee-for-Service
-
Jan 14, 2026, 21:15Cihan Ay Congratulates Cornelia Englisch on Successful Completion of Her PHD
-
Jan 14, 2026, 20:53Ana Sachetto on Reporting Negative Results
-
Jan 14, 2026, 16:22Leo Nicolai and Rainer Kaiser Link Procoagulant Platelets and Thromboinflammation in CVD